Joseph Markowitz, MD, PhD

Cancer Focus:
Melanoma

Dr. Markowitz is interested in cutaneous oncology and melanoma in particular. He will engage in clinical translational research efforts in tumor immunology and immunotherapy.

Education & Training

Board Certification:

• Internal Medicine - Medical Oncology

Fellowship:

• The Ohio State University - Medical Oncology
• The Ohio State University -
• The Ohio State University - Advanced Medical Oncology

Residency:

• The Ohio State University - Internal Medicine

Medical School:

• University of Maryland Baltimore - MD, PhD

• Dugan MM, Balsay-Patel C, Chin N, Israeli J, Ward KR, Nichols M, Greenbaum S, Fan W, Cruse CW, Harrington M, Neves RI, Gonzalez RJ, Perez MC, Sarnaik AA, Sondak VK, Messina JL, Tarhini AA, Khushalani N, Brohl AS, Markowitz J, Eroglu Z, Karapetyan L, Tsai KY, Zager JS. Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy. Ann Surg Oncol. 2026 Jan.33(1):389-396. Pubmedid: 41168606.
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov.31(11):3933. Pubmedid: 40858972.
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Nikhil IK, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov.31(11):3668-3674. Pubmedid: 40813711. Pmcid: PMC12419231.
• Weiss SA, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani NI, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger HM. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. J Clin Oncol. 2025 May.43(14):1685-1694. Pubmedid: 40048689. Pmcid: PMC12058415.
• Ospina OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, Smalley I, Tsai KY, Markowitz J, Vallebuona E, Berglund AE, Eschrich SA, Yu X, Fridley BL. spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data Analysis. Cancer Res. 2025 Mar.85(5):848-858. Pubmedid: 39636739. Pmcid: PMC11873723.
• Karapetyan L, Kuriakose J, DiMaggio E, Ward K, Chau J, Otteni C, Kalos D, Ali J, Hall MS, Beatty M, Klinkova OV, Alomar ME, Gaskill EE, Gonzalez RM, Bailey H, Yu M, Tran N, Rodriguez-Alfonso L, Vieira E, Adams K, Jain M, Locke FL, Baldonado J, Perez MC, Mullinax J, Zager JS, Gonzalez R, Sondak VK, Markowitz J, Brohl AS, Eroglu Z, Tarhini AA, Khushalani NI, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patients. Transplant Cell Ther. 2025 Dec. Pubmedid: 41421538.
• Dugan MM, Balsay-Patel C, Chin N, Israeli J, Ward KR, Nichols M, Greenbaum S, Fan W, Cruse CW, Harrington M, Neves RI, Gonzalez RJ, Perez MC, Sarnaik AA, Sondak VK, Messina JL, Tarhini AA, Khushalani N, Brohl AS, Markowitz J, Eroglu Z, Karapetyan L, Tsai KY, Zager JS. ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy. Ann Surg Oncol. 2025 Dec. Pubmedid: 41361154.
• Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Dhrubo D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodriguez-Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw TI. ShinyEvents: harmonizing longitudinal data for real world survival estimation. Res Sq. 2025 Aug. Pubmedid: 40799741. Pmcid: PMC12340904.
• Ramadoss T, Nichols M, Palacios C, Eroglu Z, Markowitz J, Karapetyan L, Tarhini AA, Wuthrick EJ, Sondak VK, Khushalani NI, Tsai KY, Brohl AS. Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma. J Immunother Cancer. 2024 Sep.12(9). Pubmedid: 39242118. Pmcid: PMC11381633.
• Tometich DB, Geiss C, Maconi ML, Chavez M, Hoogland AI, Li X, Nieves-Lopez A, Rodriguez Y, Bryant C, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Hwu P, Khushalani NI, Jim HSL. Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study. Support Care Cancer. 2024 May.32(6):330. Pubmedid: 38709312.
• Ospina OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, Smalley I, Tsai K, Markowitz J, Vallebuona E, Berglund A, Eschrich S, Yu X, Fridley BL. spatialGE: A user-friendly web application to democratize spatial transcriptomics analysis. bioRxiv. 2024 Jul. Pubmedid: 39005315. Pmcid: PMC11244876.
• Jimenez J, Dubey P, Carter B, Koomen J, Markowitz J. A metabolic perspective on nitric oxide function in melanoma. BBA. Reviews on cancer. 2024 Jan.1879(1):189038. Pubmedid: 38061664.
• Eroglu Z, Chen YA, Smalley I, Li J, Markowitz JK, Brohl AS, Tetteh L, Taylor H, Sondak VK, Khushalani NI, Smalley KSM. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma. Cancer. 2024 Jan.130(2):232-243. Pubmedid: 37776537.
• Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Delhawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Mol Cancer Ther. 2024 Aug.23(8):1139-1143. Pubmedid: 38657233. Pmcid: PMC11292317.
• Dülgar Ö, Saha A, Elleson KM, Markowitz J. Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events. Immunotherapy. 2023 Sep.15(13):993-999. Pubmedid: 37525573. Pmcid: PMC10565538.
• Garg SK, Sun J, Kim Y, Whiting J, Sarnaik A, Conejo-Garcia JR, Phelps M, Weber JS, Mulé JJ, Markowitz J. Dichotomous Nitric Oxide-Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma. Cancers (Basel). 2023 Mar.15(6). Pubmedid: 36980641. Pmcid: PMC10046641.
• Pickering C, Aiyetan P, Xu G, Mitchell A, Rice R, Najjar YG, Markowitz J, Ebert LM, Brown MP, Tapia-Rico G, Frederick D, Cong X, Serie D, Lindpaintner K, Schwarz F, Boland GM. Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy. Front Immunol. 2023 Jun.14:1187332. Pubmedid: 37388743. Pmcid: PMC10302726.
• Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, Martin J, Bui KM, Palsuledesai CC, Malhotra M, Olshan P, Markowitz J, Khushalani NI, Tarhini AA, Messina JL, Aleshin A. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023 Jun.129(11):1723-1734. Pubmedid: 36869646.
• Marin-Acevedo JA, Withycombe BM, Kim Y, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Tsai KY, Khushalani NI. Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers (Basel). 2023 Jun.15(12). Pubmedid: 37370790. Pmcid: PMC10295991.
• Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer. 2023 Feb.4(2):222-239. Pubmedid: 36690875. Pmcid: PMC9970875.
• Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
• Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J Immunother Cancer. 2022 Nov.10(11). Pubmedid: 36450385. Pmcid: PMC9717375.
• Yu X, Cen L, Chen YA, Markowitz J, Shaw TI, Tsai KY, Conejo-Garcia JR, Wang X. Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Res. 2022 May.82(9):1724-1735. Pubmedid: 35176128. Pmcid: PMC9064917.
• Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022 Jun.30(6):2315-2326. Pubmedid: 35150889. Pmcid: PMC9171150.
• Saha A, Dreyfuss I, Sarfraz H, Friedman M, Markowitz J. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. Cancers (Basel). 2022 Dec.15(1). Pubmedid: 36612082. Pmcid: PMC9817715.
• Hicks JK, Howard R, Reisman P, Adashek JJ, Fields KK, Gray JE, McIver B, McKee K, O'Leary MF, Perkins RM, Robinson E, Tandon A, Teer JK, Markowitz J, Rollison DE. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precis Oncol. 2021 May.5. Pubmedid: 34095711. Pmcid: PMC8169076.
• Creed JH, Wilson CM, Soupir AC, Colin-Leitzinger CM, Kimmel GJ, Ospina OE, Chakiryan NH, Markowitz J, Peres LC, Coghill A, Fridley BL. spatialTIME and iTIME: R package and Shiny application for visualization and analysis of immunofluorescence data. Bioinformatics. 2021 Dec.37(23):4584-4586. Pubmedid: 34734969. Pmcid: PMC8652029.
• Perkins RM, Markowitz J. Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center. Methods Mol Biol. 2020 Sep.2194:1-19. Pubmedid: 32926358.
• Sun J, Kroeger JL, Markowitz J. Introduction to Multiparametric Flow Cytometry and Analysis of High-Dimensional Data. Methods Mol Biol. 2020 Sep.2194:239-253. Pubmedid: 32926370. Pmcid: PMC7868168.
• Lin TA, Eroglu Z, Carvajal R, Markowitz J. Cohort Identification for Translational Bioinformatics Studies. Methods Mol Biol. 2020 Sep.2194:35-44. Pubmedid: 32926360. Pmcid: PMC7787345.
• Garg SK, Welsh EA, Fang B, Hernandez YI, Rose T, Gray J, Koomen JM, Berglund A, Mulé JJ, Markowitz J. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers (Basel). 2020 Nov.12(12). Pubmedid: 33255891. Pmcid: PMC7768436.
• Perkins RM, Markowitz J. Correction to: Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center. Methods Mol Biol. 2020 Nov.2194:C1. Pubmedid: 33169350.
• Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J. Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell Melanoma Res. 2020 Jan.33(1):86-95. Pubmedid: 31329344. Pmcid: PMC6928428.
• Garg SK, Ott MJ, Mostofa AGM, Chen Z, Chen YA, Kroeger J, Cao B, Mailloux AW, Agrawal A, Schaible BJ, Sarnaik A, Weber JS, Berglund AE, Mulé JJ, Markowitz J. Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy. Front Immunol. 2020 Feb.11:164. Pubmedid: 32161584. Pmcid: PMC7052497.
• Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immun. 2020 Dec.69(12):2465-2476. Pubmedid: 32556443. Pmcid: PMC7680263.
• Sun J, Kirichenko DA, Chung JL, Carr MJ, Eroglu Z, Khushalani NI, Markowitz J, Messina JL, Sondak VK, Zager JS, Patel SY. Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. World J Surg. 2020 Apr.44(4):1283-1293. Pubmedid: 31811340.
• Duggan MC, Regan-Fendt K, Olaverria Salavaggione GN, Howard JH, Stiff AR, Sabella J, Latchana N, Markowitz J, Gru A, Tridandapani S, Eisfeld AK, de la Chapelle A, Carson WE. Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy. Melanoma Res. 2019 Oct.29(5):491-500. Pubmedid: 31116161. Pmcid: PMC7088457.
• Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Ann Chen Y, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2019 May.32(3):458-469. Pubmedid: 30712316. Pmcid: PMC7771318.
• Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE. A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma. Cancer Immunol Immun. 2019 Apr.68(4):619-629. Pubmedid: 30725205. Pmcid: PMC6447692.
• Latchana N, DiVincenzo MJ, Regan K, Abrams Z, Zhang X, Jacob NK, Gru AA, Fadda P, Markowitz J, Howard JH, Carson WE. Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol. 2018 Sep.118(3):501-509. Pubmedid: 30132912. Pmcid: PMC6160327.
• Johnson DB, Bordeaux JM, Kim JY, Vaupel CA, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy JW, Witte JS, McKee SB, Ko J, Wrangle J, Dabbas B, Tangri S, Lameh J, Hall JM, Markowitz J, Balko JM, Dakappagari NK. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 Nov.24(21):5250-5260. Pubmedid: 30021908. Pmcid: PMC6214750.
• Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma. Clin Cancer Res. 2018 Nov.24(22):5516-5524. Pubmedid: 29674508. Pmcid: PMC6195480.
• Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE. Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4 T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2018 Mar.8(1):4203. Pubmedid: 29511220. Pmcid: PMC5840347.
• Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar.8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
• Perez MC, Yu HM, Markowitz J. Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy. BMJ Case Rep. 2018 Aug.2018. Pubmedid: 30108120. Pmcid: PMC6101337.
• Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson Iii WE. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immun. 2017 Nov.66(11):1437-1447. Pubmedid: 28688082. Pmcid: PMC5647220.
• Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4 T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2017 Nov.7(1):15424. Pubmedid: 29133913. Pmcid: PMC5684213.
• Puri S, Markowitz J. The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. Ann Res Hosp. 2017 May.1. Pubmedid: 31460494. Pmcid: PMC6711479.
• Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, Terando A, Markowitz J, Agnese D, Payne P, Carson WE. Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinform Biol Insights. 2017 Feb.11. Pubmedid: 28469417. Pmcid: PMC5345922.
• Yarlagadda K, Hassani J, Foote IP, Markowitz J. The role of nitric oxide in melanoma. BBA. Reviews on cancer. 2017 Dec.1868(2):500-509. Pubmedid: 28963068. Pmcid: PMC6766753.
• Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug.10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
• Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE. MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther. 2016 Sep.9:5931-5941. Pubmedid: 27729802. Pmcid: PMC5047719.
• Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, Blachly J, Walker C, Eisfeld AK, de la Chapelle A, Carson WE. Structural characterization of NRAS isoform 5. Protein Sci. 2016 May.25(5):1069-1074. Pubmedid: 26947772. Pmcid: PMC4838646.
• Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Nole TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016 Dec.7(49):81172-81186. Pubmedid: 27783987. Pmcid: PMC5348384.
• Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec.4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
• Ozgun A, Sondak VK, Markowitz J. Resistance patterns to anti-PD-1 therapy in metastatic melanoma. Chin Clin Oncol. 2016 Dec.5(6):75. Pubmedid: 27701871. Pmcid: PMC6776879.
• Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Zhu J, Markowitz J, Carson WE, Basu S, Bai XF. A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. J Immunol. 2016 Aug.197(4):1489-1497. Pubmedid: 27385779. Pmcid: PMC4975953.
• Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, Carson WE. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immun. 2015 Feb.64(2):149-159. Pubmedid: 25305035. Pmcid: PMC4504424.
• Lankenau MA, Patel R, Liyanarachchi S, Maharry SE, Hoag KW, Duggan M, Walker CJ, Markowitz J, Carson WE, Eisfeld AK, de la Chapelle A. MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci U S A. 2015 Dec.112(49):E6744-E6751. Pubmedid: 26582795. Pmcid: PMC4679059.
• Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A. 2014 Mar.111(11):4179-4184. Pubmedid: 24586049. Pmcid: PMC3964043.
• Dhar A, Mallick S, Ghosh P, Maiti A, Ahmed I, Bhattacharya S, Mandal T, Manna A, Roy K, Singh S, Nayak DK, Wilder PT, Markowitz J, Weber D, Ghosh MK, Chattopadhyay S, Guha R, Konar A, Bandyopadhyay S, Roy S. Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptide. Biopolymers. 2014 Jul.102(4):344-358. Pubmedid: 24839139. Pmcid: PMC4107132.
• Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother. 2014 Jan.37(1):55-62. Pubmedid: 24316557. Pmcid: PMC4174542.
• Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Sci Signal. 2014 Apr.7(321):ra36. Pubmedid: 24736457. Pmcid: PMC4165404.
• Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013 Jul.140(1):13-21. Pubmedid: 23828498. Pmcid: PMC3773691.
• Markowitz J, Carson WE. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta. 2013 Jan.1835(1):100-109. Pubmedid: 23123827. Pmcid: PMC3670606.
• Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013.1:10. Pubmedid: 24829747. Pmcid: PMC4019895.
• Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep.15(18):5895-5901. Pubmedid: 19737952. Pmcid: PMC2774354.
• Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont). 2008 Oct.5(10):29-36. Pubmedid: 19724721. Pmcid: PMC2695757.
• Markowitz J, MacKerell AD, Weber DJ. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem. 2007 Jun.7(6):609-616. Pubmedid: 17584159.
• Wright NT, Varney KM, Ellis KC, Markowitz J, Gitti RK, Zimmer DB, Weber DJ. The three-dimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy. J Mol Biol. 2005 Oct.353(2):410-426. Pubmedid: 16169012.
• Markowitz J, Rustandi RR, Varney KM, Wilder PT, Udan R, Wu SL, Horrocks WD, Weber DJ. Calcium-binding properties of wild-type and EF-hand mutants of S100B in the presence and absence of a peptide derived from the C-terminal negative regulatory domain of p53. Biochemistry-Us. 2005 May.44(19):7305-7314. Pubmedid: 15882069.
• Markowitz J, Mackerell AD, Carrier F, Charpentier TH, Weber DJ. Design of Inhibitors for S100B. Curr Top Med Chem. 2005.5(12):1093-1108. Pubmedid: 16248785.
• Markowitz J, Chen I, Gitti R, Baldisseri DM, Pan Y, Udan R, Carrier F, MacKerell AD, Weber DJ. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J Med Chem. 2004 Oct.47(21):5085-5093. Pubmedid: 15456252.
• Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004 Aug.279(32):34071-34077. Pubmedid: 15178678.
• Lee ME, Markowitz J, Lee JO, Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 2002 Oct.530(1-3):53-58. Pubmedid: 12387865.

• Title: Modeling nitric oxide in melanoma to improve efficacy of single-agent immunotherapy
  Award Number: 09336612607
  Sponsor: Moffitt Cancer Center
  Markowitz, J. (PD/PI), West, J. (PD/PI)
• Title: Nitric Oxide Immune Dependent Resistance Mechanisms to Anti-PD-1 Therapy
  Award Number: 5K08CA252164-03
  Sponsor: National Cancer Institute (NCI)
  Markowitz, J. (PD/PI)
• Title: IFx-Hu2.0 facilitates immune responses in melanoma
  Award Number: 23B05
  Sponsor: Florida Department of Health
  Markowitz, J. (PD/PI)